Broader Power

Lawmakers in the US may vote this week on legislation that would give the Food and Drug Administration broader authorities and would renew the law governing the user fees that FDA collects to review drugs and medical devices, reports The Wall Street Journal. The Journal notes that both versions of the bill give FDA regulatory authority over foreign raw materials for drugs, as FDA now "has limited ability to require safety inspections of foreign drug facilities." Additionally, under the law, drug companies would pay about 6 percent more in user fees, or $4 billon over five years, and medical device companies would see a doubling in fees to $600 million over five years, the report adds.